DK1132086T3 - Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt - Google Patents

Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt

Info

Publication number: DK1132086T3
Authority: DK; Denmark
Prior art keywords: acute; agonists; renal failure; prostaglandin; chronic renal
Prior art date: 2000-01-31

Application number

DK01300690T

Other languages

Danish (da)

English (en)

Inventor

David Duane Thompson

Vishwas Madhav Paralkar

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-31

Filing date

2001-01-25

Publication date

2006-08-28

2001-01-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-08-28 Application granted granted Critical

2006-08-28 Publication of DK1132086T3 publication Critical patent/DK1132086T3/da

Links

239000000556 agonist Substances 0.000 title abstract 3
150000003180 prostaglandins Chemical class 0.000 title abstract 3
208000009304 Acute Kidney Injury Diseases 0.000 title abstract 2
208000033626 Renal failure acute Diseases 0.000 title abstract 2
230000001154 acute effect Effects 0.000 title abstract 2
201000011040 acute kidney failure Diseases 0.000 title abstract 2
208000012998 acute renal failure Diseases 0.000 title abstract 2
208000020832 chronic kidney disease Diseases 0.000 title abstract 2
208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title 1
229960002986 dinoprostone Drugs 0.000 title 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title 1
101150109738 Ptger4 gene Proteins 0.000 abstract 1
230000004064 dysfunction Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK01300690T 2000-01-31 2001-01-25 Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt DK1132086T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US17896800P	2000-01-31	2000-01-31

Publications (1)

Publication Number	Publication Date
DK1132086T3 true DK1132086T3 (da)	2006-08-28

Family

ID=22654657

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01300690T DK1132086T3 (da)	2000-01-31	2001-01-25	Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt

Country Status (18)

Country	Link
US (1)	US6610719B2 (de)
EP (1)	EP1132086B1 (de)
JP (2)	JP3839261B2 (de)
KR (1)	KR100419684B1 (de)
AT (1)	ATE327751T1 (de)
AU (1)	AU774569B2 (de)
CA (1)	CA2332687A1 (de)
CO (1)	CO5261529A1 (de)
CY (1)	CY1105299T1 (de)
DE (1)	DE60120007T2 (de)
DK (1)	DK1132086T3 (de)
ES (1)	ES2263557T3 (de)
HU (1)	HUP0100495A3 (de)
IL (1)	IL141120A0 (de)
NZ (1)	NZ509632A (de)
PE (1)	PE20011048A1 (de)
PT (1)	PT1132086E (de)
ZA (1)	ZA200100827B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001290250A1 (en) *	2000-09-21	2002-04-02	Ono Pharmaceutical Co. Ltd.	Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
OA12533A (en) *	2000-11-27	2006-06-05	Pfizer Prod Inc	Ep4 receptor selective agonists in the treatment of osteoporosis.
CN100371322C (zh) *	2001-07-16	2008-02-27	霍夫曼-拉罗奇有限公司	作为前列腺素类化合物激动剂的2-吡咯烷酮衍生物
EP2255829A3 (de) *	2001-07-23	2012-03-28	Ono Pharmaceutical Co., Ltd.	Pharmazeutische Zusammensetzung zur Behandlung von Erkrankungen, die mit Knochenschwund einhergehen, mit EP4-Agonist als Wirkstoff
US7410991B2 (en)	2001-10-23	2008-08-12	Laboratoires Serono S.A.	Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
US20040254230A1 (en) *	2001-12-03	2004-12-16	Ogidigben Miller J.	Method for treating ocular hypertension
AU2003211574A1 (en)	2002-03-05	2003-09-16	Ono Pharmaceutical Co., Ltd.	8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
EP1490055A1 (de) *	2002-03-18	2004-12-29	Pfizer Products Inc.	Verwendung von selektiven ep4 rezeptor-agonisten zur behandlung von leberinsuffizienz, verlust der durchgängigkeit des ductus arteriosus, glaukom oder okularer hypertonie
US6573294B1 (en)	2002-05-14	2003-06-03	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2003233729B2 (en) *	2002-06-06	2007-10-04	Merck Frosst Canada Ltd	1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
JP4754820B2 (ja) *	2002-06-10	2011-08-24	メルクセローノソシエテアノニム	プロスタグランジン作動薬としてのγラクタムおよびその使用
ES2584606T3 (es)	2002-10-10	2016-09-28	Ono Pharmaceutical Co., Ltd.	Microesferas que comprenden ONO-1301
FI20030015A0 (fi) *	2003-01-03	2003-01-03	Orion Corp	Menetelmä munuaisten vajaatoiminnan hoitamiseksi
US7256211B1 (en)	2003-01-21	2007-08-14	Ono Pharmaceutical Co., Ltd.	8-azaprostaglandin derivatives and medical use thereof
GB0302094D0 (en)	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
US6734206B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
GB0324269D0 (en) *	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
US20080306155A1 (en) *	2004-09-16	2008-12-11	Roman Richard J	Method for treating renal disease
US7893107B2 (en) *	2005-11-30	2011-02-22	Allergan, Inc.	Therapeutic methods using prostaglandin EP4 agonist components
US20070232660A1 (en) *	2006-04-04	2007-10-04	Allergan, Inc.	Therapeutic and delivery methods of prostaglandin ep4 agonists
US9394520B2 (en)	2006-12-08	2016-07-19	University Of Rochester	Expansion of hematopoietic stem cells
EP1952823A1 (de)	2007-01-30	2008-08-06	AM-Pharma B.V.	Verwendung von alkalischer Phosphatase bei der Behandlung eingeschränkter Nierenfunktion
EP2408444A4 (de)	2009-03-19	2012-09-26	Fate Therapeutics Inc	Zusammensetzungen mit cyclischen amp-verstärkern und/oder ep-liganden sowie verfahren zu ihrer herstellung und verwendung
CA2738045C (en)	2010-05-28	2019-02-19	Simon Fraser University	Conjugate compounds, methods of making same, and uses thereof
CA2802414C (en)	2010-06-17	2018-01-09	Nitto Denko Corporation	Agent for treating renal fibrosis
EP2603227B1 (de)	2010-08-12	2017-10-04	Fate Therapeutics, Inc.	Verbesserte hämatopoetische stamm- und vorläuferzelltherapie
WO2013018837A1 (ja) *	2011-08-02	2013-02-07	小野薬品工業株式会社	左室拡張機能改善剤
PT2760994T (pt)	2011-09-30	2017-08-24	Bluebird Bio Inc	Compostos para melhor transdução viral
EP3785767A1 (de)	2011-12-02	2021-03-03	Fate Therapeutics, Inc.	Verbesserte stammzellenzusammensetzung
US10111907B2 (en)	2011-12-02	2018-10-30	Fate Therapeutics, Inc.	Methods of treating ischemia
ES2733998T3 (es)	2012-10-29	2019-12-03	Cardio Incorporated	Agente terapéutico específico de enfermedad pulmonar
US9943545B2 (en)	2013-03-15	2018-04-17	Fate Therapeutics, Inc.	Stem cell culture media and methods of enhancing cell survival
US10851412B2 (en)	2013-03-15	2020-12-01	Fate Therapeutics, Inc.	Cell potency assay for therapeutic potential
US9968716B2 (en)	2013-10-15	2018-05-15	Ono Pharmaceutical Co., Ltd.	Drug-eluting stent graft
EP3097188B1 (de)	2014-01-24	2018-08-29	AM-Pharma B.V.	Weiterverarbeitung von alkalischer phosphatase
US9926544B2 (en)	2014-01-24	2018-03-27	Am-Pharma B.V.	Chimeric alkaline phosphatase-like proteins
US9650414B1 (en)	2014-05-30	2017-05-16	Simon Fraser University	Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
US20180112180A1 (en)	2015-01-26	2018-04-26	Fate Therapeutics, Inc.	Cells with increased immuno-regulatory properties and methods for their use and manufacture
CN107849072B (zh)	2015-06-12	2020-12-15	西蒙弗雷泽大学	酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
RU2018106515A (ru)	2015-07-21	2019-08-21	Зе Чилдрен'С Медикал Сентер Корпорейшн	Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
WO2017139576A1 (en)	2016-02-12	2017-08-17	Bluebird Bio, Inc.	Vcn enhancer compositions and methods of using the same
WO2017139561A1 (en)	2016-02-12	2017-08-17	Bluebird Bio, Inc.	Vcn enhancer compositions and methods of using the same
EP3423067B1 (de)	2016-03-04	2025-07-23	The Board of Trustees of the Leland Stanford Junior University	Inhibitoren der 15-hydroxyprostaglandin-dehydrogenase für die muskelregeneration
WO2018227138A1 (en)	2017-06-09	2018-12-13	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for preventing or treating muscle conditions
WO2019060708A1 (en)	2017-09-22	2019-03-28	The Children's Medical Center Corporation	TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
EP4146797A1 (de)	2020-05-06	2023-03-15	Orchard Therapeutics (Europe) Limited	Behandlung von neurodegenerativen erkrankungen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4066692A (en)	1972-10-30	1978-01-03	Merck & Co., Inc.	11,12-secoprostaglandins
US3987091A (en)	1973-04-12	1976-10-19	Merck & Co., Inc.	11,12-secoprostaglandins
US4033996A (en)	1973-04-25	1977-07-05	Merck & Co., Inc.	8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
SE7414770L (de)	1973-12-13	1975-06-16	Merck & Co Inc
US3991087A (en)	1973-12-13	1976-11-09	Merck & Co., Inc.	8-Halo-11,12-secoprostaglandins
DK366475A (da)	1974-08-30	1976-03-01	Merck & Co Inc	Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US4055596A (en)	1974-09-13	1977-10-25	Merck & Co., Inc.	11,12-Seco-prostaglandins
US3991106A (en)	1974-09-13	1976-11-09	Merck & Co., Inc.	16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4177346A (en)	1976-08-06	1979-12-04	Pfizer Inc.	1,5-Disubstituted-2-pyrrolidones
SE423813B (sv) *	1976-08-06	1982-06-07	Pfizer	Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4175203A (en)	1976-12-17	1979-11-20	Merck & Co., Inc.	Interphenylene 11,12-secoprostaglandins
US4112236A (en)	1977-04-04	1978-09-05	Merck & Co., Inc.	Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US5605814A (en)	1993-08-31	1997-02-25	Merck Frosst Canada Inc.	DNA encoding human prostaglandin receptor EP2
US5716835A (en)	1994-05-05	1998-02-10	Allergan, Inc.	Nucleic acid encoding a novel human EP prostaglandin receptor
US5807895A (en) *	1994-11-29	1998-09-15	Schwarz Pharma, Inc.	Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
UA59384C2 (uk)	1996-12-20	2003-09-15	Пфайзер, Інк.	Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
JPH10265454A (ja)	1997-01-27	1998-10-06	Ono Pharmaceut Co Ltd	３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AU7349298A (en)	1997-06-23	1999-01-04	Pfizer Inc.	Prostaglandin agonists
SE9702681D0 (sv)	1997-07-10	1997-07-10	Pharmacia & Upjohn Ab	Method and composition for treatment of impotence
UA67754C2 (uk)	1997-10-10	2004-07-15	Пфайзер, Інк.	Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6124314A (en)	1997-10-10	2000-09-26	Pfizer Inc.	Osteoporosis compounds
TWI249520B (en) *	1998-07-15	2006-02-21	Ono Pharmaceutical Co	5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
KR20010074981A (ko) *	1998-09-14	2001-08-09	우에노 도시오	ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
WO2000054808A1 (fr) *	1999-03-16	2000-09-21	Toray Industries, Inc.	Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant

2001
- 2001-01-25 IL IL14112001A patent/IL141120A0/xx unknown
- 2001-01-25 PT PT01300690T patent/PT1132086E/pt unknown
- 2001-01-25 DK DK01300690T patent/DK1132086T3/da active
- 2001-01-25 AT AT01300690T patent/ATE327751T1/de not_active IP Right Cessation
- 2001-01-25 DE DE60120007T patent/DE60120007T2/de not_active Expired - Fee Related
- 2001-01-25 ES ES01300690T patent/ES2263557T3/es not_active Expired - Lifetime
- 2001-01-25 EP EP01300690A patent/EP1132086B1/de not_active Expired - Lifetime
- 2001-01-29 US US09/771,164 patent/US6610719B2/en not_active Expired - Fee Related
- 2001-01-29 CA CA002332687A patent/CA2332687A1/en not_active Abandoned
- 2001-01-29 PE PE2001000097A patent/PE20011048A1/es not_active Application Discontinuation
- 2001-01-30 JP JP2001021534A patent/JP3839261B2/ja not_active Expired - Fee Related
- 2001-01-30 NZ NZ509632A patent/NZ509632A/xx unknown
- 2001-01-30 AU AU16722/01A patent/AU774569B2/en not_active Ceased
- 2001-01-30 HU HU0100495A patent/HUP0100495A3/hu unknown
- 2001-01-30 ZA ZA200100827A patent/ZA200100827B/xx unknown
- 2001-01-31 CO CO01007013A patent/CO5261529A1/es not_active Application Discontinuation
- 2001-01-31 KR KR10-2001-0004590A patent/KR100419684B1/ko not_active Expired - Fee Related
2006
- 2006-02-24 JP JP2006047746A patent/JP2006182788A/ja active Pending
- 2006-07-04 CY CY20061100920T patent/CY1105299T1/el unknown

Also Published As

Publication number	Publication date
ZA200100827B (en)	2002-07-30
DE60120007T2 (de)	2006-11-16
IL141120A0 (en)	2002-02-10
ES2263557T3 (es)	2006-12-16
JP3839261B2 (ja)	2006-11-01
JP2001233792A (ja)	2001-08-28
NZ509632A (en)	2003-01-31
KR20010078209A (ko)	2001-08-20
HUP0100495A2 (en)	2002-10-28
HUP0100495A3 (en)	2003-12-29
EP1132086A3 (de)	2002-01-09
HU0100495D0 (en)	2001-03-28
CO5261529A1 (es)	2003-03-31
PT1132086E (pt)	2006-09-29
DE60120007D1 (de)	2006-07-06
PE20011048A1 (es)	2001-10-19
AU774569B2 (en)	2004-07-01
CY1105299T1 (el)	2010-03-03
CA2332687A1 (en)	2001-07-31
US20010041729A1 (en)	2001-11-15
ATE327751T1 (de)	2006-06-15
EP1132086B1 (de)	2006-05-31
AU1672201A (en)	2001-08-02
EP1132086A2 (de)	2001-09-12
JP2006182788A (ja)	2006-07-13
US6610719B2 (en)	2003-08-26
KR100419684B1 (ko)	2004-02-21

Publication	Publication Date	Title
DK1132086T3 (da)	2006-08-28	Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt
PT1305286E (pt)	2005-04-29	Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
DK1202724T3 (da)	2004-01-26	Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
IS6950A (is)	2003-09-12	Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma
EA200601553A1 (ru)	2006-12-29	Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
NL1021454A1 (nl)	2003-03-17	Wassen van CO2 uit methaan bevattende gassen onder toepassing van een waterige stroom.
DK1379239T3 (da)	2008-01-07	N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
EA200601552A1 (ru)	2007-02-27	Замещенные конденсированные гетероциклические с-гликозиды
NO20080612L (no)	2008-04-30	Immunokonjugatpreparater
DK1682530T3 (da)	2007-07-16	Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA200301142A1 (ru)	2004-02-26	Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
DK1117403T3 (da)	2004-04-13	MGLUR5-antagonister til behandling af smerte og angst
DK1456212T3 (da)	2007-04-02	6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
SE9702681D0 (sv)	1997-07-10	Method and composition for treatment of impotence
DK1373220T3 (da)	2007-10-08	Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
DK1448562T3 (da)	2007-09-24	Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
DE60029242D1 (de)	2006-08-17	Arzneien zur begleitenden behandlung von glaukomen
ATE443044T1 (de)	2009-10-15	Tace inhibitoren
BRPI0516128A (pt)	2008-08-26	uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
WO2002041894A3 (en)	2002-10-17	Selective dopamine d4 receptor agonists for treating sexual dysfunction
DK1658062T3 (da)	2010-05-31	Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
DK1301475T3 (da)	2007-04-02	Arylsulfonamider, som serotoninantagonist til behandling af obesitet
DK1177191T3 (da)	2004-04-05	Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
DK1455770T3 (da)	2007-10-08	Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DK1223930T3 (da)	2006-11-20	Behandling af dyskinesi